Canada markets closed

ARCA biopharma, Inc. (ABIO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.0601+0.0101 (+0.49%)
At close: 03:44PM EST
2.2000 +0.14 (+6.79%)
After hours: 05:18PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close2.0500
Open2.0800
Bid2.0200 x 1000
Ask2.3200 x 900
Day's Range2.0300 - 2.1000
52 Week Range1.7100 - 2.5900
Volume20,988
Avg. Volume28,614
Market Cap29.686M
Beta (5Y Monthly)1.82
PE Ratio (TTM)N/A
EPS (TTM)-1.2830
Earnings DateOct 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Simply Wall St.

    One ARCA biopharma, Inc. (NASDAQ:ABIO) insider upped their stake by 5,155% in the previous year

    Viewing insider transactions for ARCA biopharma, Inc.'s ( NASDAQ:ABIO ) over the last year, we see that insiders were...

  • GlobeNewswire

    ARCA biopharma Announces Third Quarter 2022 Financial Results

    Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER, Colo., Oct. 28, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported third quarter 2022 financial results and provided a corporate update. In May 2022, the Company retaine

  • GlobeNewswire

    ARCA biopharma Announces Second Quarter 2022 Financial Results

    Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2022 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s Pr